Evidence map›Paper›PMID 26257060›Full record

ArticleOncogene2016

GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm.

K Taki, M Ohmuraya, E Tanji, H Komatsu, D Hashimoto, K Semba, K Araki, Y Kawaguchi, H Baba, T Furukawa

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 89 citations in OpenAlex.

  1. Review
  2. Dual Role of NRF2 in Pancreatic Precursor Lesions.Cancer research communications · 2025
    Article
  3. Review
  4. Article
  5. Contract to kill: GNAS mutation.Molecular cancer · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Clinical and Molecular Attributes and Evaluation of Pancreatic Cystic Neoplasm.Biochimica et biophysica acta. Reviews on cancer · 2023
    Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

K TakiInstitute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan.
M OhmurayaInstitute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan.
E TanjiInstitute for Integrated Medical Sciences, Tokyo Women's Medical University, Tokyo, Japan.
H KomatsuInstitute for Integrated Medical Sciences, Tokyo Women's Medical University, Tokyo, Japan.
D HashimotoDepartment of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan.
K SembaInstitute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan.
K ArakiInstitute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan.
Y KawaguchiCenter for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
H BabaDepartment of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan.
T FurukawaInstitute for Integrated Medical Sciences, Tokyo Women's Medical University, Tokyo, Japan.
Kumamoto University · JPTokyo Women's Medical University · JPKyoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intraductal papillary mucinous neoplasm (IPMN), the most common pancreatic cystic neoplasm, is known to progress to invasive ductal adenocarcinoma. IPMNs commonly harbor activating somatic mutations in GNAS and KRAS, primarily GNAS(R201H) and KRAS(G12D). GNAS encodes the stimulatory G-protein α subunit (Gsα) that mediates a stimulatory signal to adenylyl cyclase to produce cyclic adenosine monophosphate (cAMP), subsequently activating cAMP-dependent protein kinase A. The GNAS(R201H) mutation results in constitutive activation of Gsα. To study the potential role of GNAS in pancreatic tumorigenesis in vivo, we generated lines of transgenic mice in which the transgene consisted of Lox-STOP-Lox (LSL)-GNAS(R201H) under the control of the CAG promoter (Tg(CAG-LSL-GNAS)). These mice were crossed with pancreatic transcription factor 1a (Ptf1a)-Cre mice (Ptf1a(Cre/+)), generating Tg(CAG-LSL-GNAS);Ptf1a(Cre/+) mice. This mouse line showed elevated cAMP levels, small dilated tubular complex formation, loss of acinar cells and fibrosis in the pancreas; however, no macroscopic tumorigenesis was apparent by 2 months of age. We then crossed Tg(CAG-LSL-GNAS);Ptf1a(Cre/+) mice with LSL-Kras(G12D) mice, generating Tg(CAG-LSL-GNAS);LSL-Kras(G12D);Ptf1a(Cre/+) mice. We used these mice to investigate a possible cooperative effect of GNAS(R201H) and Kras(G12D) in pancreatic tumorigenesis. Within 5 weeks, Tg(CAG-LSL-GNAS);LSL-Kras(G12D);Ptf1a(Cre/+) mice developed a cystic tumor consisting of marked dilated ducts lined with papillary dysplastic epithelia in the pancreas, which closely mimicked the human IPMN. Our data strongly suggest that activating mutations in GNAS and Kras cooperatively promote murine pancreatic tumorigenesis, which recapitulates IPMN. Our mouse model may serve as a unique in vivo platform to find biomarkers and effective drugs for diseases associated with GNAS mutations.

Indexed as

MutationAnimalsCarcinogenesisCarcinoma, Pancreatic DuctalChromograninsFemaleGTP-Binding Protein alpha Subunits, GsHumansMaleMicePancreatic NeoplasmsProto-Oncogene Proteins p21(ras)ChromograninsGNAS protein, humanGTP-Binding Protein alpha Subunits, GsProto-Oncogene Proteins p21(ras)

Identifiers

PMID26257060
OpenAlexW2253146128

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.